ACE2 and infection: Franco and co-workers tested the effects of EIDD-1931, another licensed repurposed antiviral against SARS-CoV-2 (the active form of Molnupiravir), and demonstrated an SI of 12.5 against Omicron infection in A549-ACE2 cells [90].